Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma

Trial Profile

Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Lenalidomide (Primary) ; Autologous stem cell therapy; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms AMM2011
  • Most Recent Events

    • 20 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top